

# Patrick G Kehoe

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6004648/patrick-g-kehoe-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

192  
papers

12,398  
citations

50  
h-index

107  
g-index

214  
ext. papers

14,851  
ext. citations

7  
avg, IF

5.96  
L-index

#	Paper	IF	Citations
192	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. <i>Nature Genetics</i> , <b>2009</b> , 41, 1088-93	36.3	2018
191	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. <i>Nature Genetics</i> , <b>2011</b> , 43, 429-35	36.3	1421
190	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A $\beta$ tau, immunity and lipid processing. <i>Nature Genetics</i> , <b>2019</b> , 51, 414-430	36.3	917
189	Abeta-degrading enzymes in Alzheimer's disease. <i>Brain Pathology</i> , <b>2008</b> , 18, 240-52	6	279
188	A full genome scan for late onset Alzheimer's disease. <i>Human Molecular Genetics</i> , <b>1999</b> , 8, 237-45	5.6	279
187	Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. <i>PLoS ONE</i> , <b>2010</b> , 5, e13950	3.7	276
186	Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. <i>Nature Genetics</i> , <b>1999</b> , 21, 71-2	36.3	236
185	Drug repositioning for Alzheimer's disease. <i>Nature Reviews Drug Discovery</i> , <b>2012</b> , 11, 833-46	64.1	191
184	A $\beta$ -degrading enzymes: potential for treatment of Alzheimer disease. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2011</b> , 70, 944-59	3.1	185
183	Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. <i>American Journal of Epidemiology</i> , <b>2005</b> , 162, 305-17	3.8	170
182	Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. <i>Journal of Alzheimer's Disease</i> , <b>2011</b> , 26, 699-708	4.3	168
181	Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier. <i>Chemical Reviews</i> , <b>2013</b> , 113, 1877-903	68.1	160
180	Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?. <i>Lancet Neurology</i> , <b>2007</b> , 6, 373-8	24.1	145
179	Vascular cognitive impairment neuropathology guidelines (VCING): the contribution of cerebrovascular pathology to cognitive impairment. <i>Brain</i> , <b>2016</b> , 139, 2957-2969	11.2	141
178	Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 280-292	1.2	136
177	Angiotensins in Alzheimer's disease - friend or foe?. <i>Trends in Neurosciences</i> , <b>2009</b> , 32, 619-28	13.3	135
176	Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism. <i>Human Mutation</i> , <b>2004</b> , 23, 358-67	4.7	114

175	Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2006</b> , 65, 1012-21	3.1	112
174	Angiotensin-converting enzyme 2 is reduced in Alzheimer's disease in association with increasing amyloid- $\beta$ and tau pathology. <i>Alzheimer's Research and Therapy</i> , <b>2016</b> , 8, 50	9	107
173	The Vascular Impairment of Cognition Classification Consensus Study. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 624-633	1.2	106
172	Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. <i>Neuropathology and Applied Neurobiology</i> , <b>2008</b> , 34, 181-93	5.2	106
171	Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer's disease. <i>PLoS ONE</i> , <b>2015</b> , 10, e0119452	3.7	105
170	The cardiovascular and respiratory health of people with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , <b>2006</b> , 113, 298-305	6.5	99
169	Haplotypes extending across ACE are associated with Alzheimer's disease. <i>Human Molecular Genetics</i> , <b>2003</b> , 12, 859-67	5.6	93
168	Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. <i>American Journal of Neurodegenerative Disease</i> , <b>2014</b> , 3, 19-32	2.5	89
167	Alpha-2 macroglobulin gene and Alzheimer disease. <i>Nature Genetics</i> , <b>1999</b> , 22, 17-9; author reply 21-2	36.3	88
166	Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes. <i>American Journal of Translational Research (discontinued)</i> , <b>2009</b> , 1, 163-77	3	88
165	Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by Abeta. <i>American Journal of Pathology</i> , <b>2009</b> , 175, 262-70	5.8	87
164	CNS SIRT3 expression is altered by reactive oxygen species and in Alzheimer's disease. <i>PLoS ONE</i> , <b>2012</b> , 7, e48225	3.7	87
163	Endothelin-1 is elevated in Alzheimer's disease and upregulated by amyloid- $\beta$ <i>Journal of Alzheimer's Disease</i> , <b>2012</b> , 29, 853-61	4.3	81
162	VEGF-A165b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor A in vivo and in vitro. <i>American Journal of Pathology</i> , <b>2013</b> , 183, 918-29	5.8	78
161	Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2009</b> , 68, 902-14	3.1	78
160	Changes with age in the activities of beta-secretase and the Abeta-degrading enzymes neprilysin, insulin-degrading enzyme and angiotensin-converting enzyme. <i>Brain Pathology</i> , <b>2010</b> , 20, 794-802	6	76
159	Distribution and expression of picalm in Alzheimer disease. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2010</b> , 69, 1071-7	3.1	76
158	Cognitive impact of COVID-19: looking beyond the short term. <i>Alzheimer's Research and Therapy</i> , <b>2020</b> , 12, 170	9	76

157	Pathophysiology of white matter perfusion in Alzheimer's disease and vascular dementia. <i>Brain</i> , <b>2014</b> , 137, 1524-32	11.2	75
156	The Coming of Age of the Angiotensin Hypothesis in Alzheimer's Disease: Progress Toward Disease Prevention and Treatment?. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 62, 1443-1466	4.3	73
155	Alzheimer's disease-like pathology has transient effects on the brain and blood metabolome. <i>Neurobiology of Aging</i> , <b>2016</b> , 38, 151-163	5.6	70
154	Metabolomic Profiling of Bile Acids in Clinical and Experimental Samples of Alzheimer's Disease. <i>Metabolites</i> , <b>2017</b> , 7,	5.6	67
153	Aluminum in the Diet and Alzheimer's Disease: From Current Epidemiology to Possible Disease-Modifying Treatment. <i>Journal of Alzheimer's Disease</i> , <b>2010</b> , 20, 17-30	4.3	67
152	Sex differences in the association of apolipoprotein E and angiotensin-converting enzyme gene polymorphisms with healthy aging and longevity: a population-based study from Southern Italy. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , <b>2006</b> , 61, 918-23	6.4	62
151	Vascular risk and genetics of sporadic late-onset Alzheimer's disease. <i>Journal of Neural Transmission</i> , <b>2004</b> , 111, 69-89	4.3	58
150	ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer's disease. <i>Acta Neuropathologica</i> , <b>2020</b> , 139, 485-502	14.3	56
149	Tumour necrosis factor-alpha gene polymorphisms and Alzheimer's disease. <i>Neuroscience Letters</i> , <b>2003</b> , 350, 61-5	3.3	55
148	APOE epsilon 4 influences the manifestation of Alzheimer's disease in adults with Down's syndrome. <i>British Journal of Psychiatry</i> , <b>2000</b> , 176, 468-72	5.4	54
147	Presenilin-1 polymorphism and Alzheimer's disease. <i>Lancet, The</i> , <b>1996</b> , 347, 1185-1187	4.0	54
146	Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 40, 595-603	4.3	53
145	Angiotensin I converting enzyme (ACE) gene polymorphism in centenarians: different allele frequencies between the North and South of Europe. <i>Experimental Gerontology</i> , <b>2003</b> , 38, 1015-20	4.5	52
144	Insights into the pathogenesis and pathogenicity of cerebral amyloid angiopathy. <i>Frontiers in Bioscience - Landmark</i> , <b>2009</b> , 14, 4778-92	2.8	50
143	Familial influence on variation in age of onset and behavioural phenotype in Alzheimer's disease. <i>British Journal of Psychiatry</i> , <b>2000</b> , 176, 156-9	5.4	50
142	BIN1 is decreased in sporadic but not familial Alzheimer's disease or in aging. <i>PLoS ONE</i> , <b>2013</b> , 8, e78806	3.7	49
141	The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: current standing of the angiotensin hypothesis?. <i>Journal of Alzheimer's Disease</i> , <b>2012</b> , 30 Suppl 2, S251-68	4.3	48
140	The role of variation at ABP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2012</b> , 28, 377-87	4.3	47

139	A cladistic model of ACE sequence variation with implications for myocardial infarction, Alzheimer disease and obesity. <i>Human Molecular Genetics</i> , <b>2004</b> , 13, 2647-57	5.6	47
138	The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 195-206.e1	1.2	45
137	Distribution of the branched chain aminotransferase proteins in the human brain and their role in glutamate regulation. <i>Journal of Neurochemistry</i> , <b>2012</b> , 123, 997-1009	6	45
136	No association between the alpha-2 macroglobulin I1000V polymorphism and Alzheimer's disease. <i>Neuroscience Letters</i> , <b>1999</b> , 262, 137-9	3.3	45
135	Age-associated changes of brain copper, iron, and zinc in Alzheimer's disease and dementia with Lewy bodies. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 42, 1407-13	4.3	44
134	Interdisciplinary challenges and promising theranostic effects of nanoscience in Alzheimer's disease. <i>RSC Advances</i> , <b>2012</b> , 2, 5008	3.7	44
133	Oligomeric Aβeta in Alzheimer's disease: relationship to plaque and tangle pathology, APOE genotype and cerebral amyloid angiopathy. <i>Brain Pathology</i> , <b>2010</b> , 20, 468-80	6	44
132	Transferrin and HFE genes interact in Alzheimer's disease risk: the Epistasis Project. <i>Neurobiology of Aging</i> , <b>2012</b> , 33, 202.e1-13	5.6	43
131	The dopamine βhydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project. <i>BMC Medical Genetics</i> , <b>2010</b> , 11, 162	2.1	43
130	Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain. <i>Neurobiology of Aging</i> , <b>2005</b> , 26, 795-802	5.6	42
129	Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , <b>2013</b> , 22, 1229-42	5.9	41
128	Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease. <i>Journal of Neuroinflammation</i> , <b>2009</b> , 6, 22	10.1	41
127	Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, Aβeta, and Alzheimer's disease. <i>PLoS ONE</i> , <b>2010</b> , 5, e8764	3.7	40
126	Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid. <i>Journal of Neuroscience Methods</i> , <b>2008</b> , 167, 229-36	3	39
125	Genetic variability at the amyloid-beta precursor protein locus may contribute to the risk of late-onset Alzheimer's disease. <i>Neuroscience Letters</i> , <b>1999</b> , 269, 67-70	3.3	39
124	Investigation of antihypertensive class, dementia, and cognitive decline: A meta-analysis. <i>Neurology</i> , <b>2020</b> , 94, e267-e281	6.5	38
123	The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2014</b> , 6, 27	9	38
122	Higher soluble amyloid beta concentration in frontal cortex of young adults than in normal elderly or Alzheimer's disease. <i>Brain Pathology</i> , <b>2010</b> , 20, 787-93	6	38

121	Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations. <i>PLoS ONE</i> , <b>2017</b> , 12, e0179521	3.7	36
120	The SIRT2 polymorphism rs10410544 and risk of Alzheimer's disease in two Caucasian case-control cohorts. <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, 392-9	1.2	36
119	A $\beta$ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes. <i>Frontiers in Aging Neuroscience</i> , <b>2014</b> , 6, 238	5.3	34
118	Oxidative balance in Alzheimer's disease: relationship to APOE, Braak tangle stage, and the concentrations of soluble and insoluble amyloid- $\beta$ . <i>Journal of Alzheimer's Disease</i> , <b>2010</b> , 22, 1363-73	4.3	34
117	The renin-angiotensin-aldosterone system and Alzheimer's disease?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , <b>2003</b> , 4, 80-93	3	34
116	APOE promoter, ACE1 and CYP46 polymorphisms and beta-amyloid in Alzheimer's disease. <i>NeuroReport</i> , <b>2004</b> , 15, 95-8	1.7	34
115	Neprilysin protects against cerebral amyloid angiopathy and A $\beta$ -induced degeneration of cerebrovascular smooth muscle cells. <i>Brain Pathology</i> , <b>2011</b> , 21, 594-605	6	33
114	Kallikrein-related peptidase 6 in Alzheimer's disease and vascular dementia. <i>Brain Research</i> , <b>2010</b> , 1363, 1-10	3.7	33
113	Common variants of ACE contribute to variable age-at-onset of Alzheimer's disease. <i>Human Genetics</i> , <b>2004</b> , 114, 478-83	6.3	33
112	Effects of Hypertension and Anti-Hypertensive Treatment on Amyloid- $\beta$ Plaque Load and A $\beta$ -Synthesizing and A $\beta$ -Degrading Enzymes in Frontal Cortex. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 50, 1191-203	4.3	33
111	The association of multiple anti-hypertensive medication classes with Alzheimer's disease incidence across sex, race, and ethnicity. <i>PLoS ONE</i> , <b>2018</b> , 13, e0206705	3.7	33
110	The sex-specific associations of the aromatase gene with Alzheimer's disease and its interaction with IL10 in the Epistasis Project. <i>European Journal of Human Genetics</i> , <b>2014</b> , 22, 216-20	5.3	32
109	Single-domain amnesic mild cognitive impairment identified by cluster analysis predicts Alzheimer's disease in the european prospective DESCRIPA study. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2013</b> , 36, 1-19	2.6	32
108	Plasminogen and plasmin in Alzheimer's disease. <i>Brain Research</i> , <b>2010</b> , 1355, 7-15	3.7	32
107	Positive association between risk for late-onset Alzheimer disease and genetic variation in IDE. <i>Neurobiology of Aging</i> , <b>2007</b> , 28, 1374-80	5.6	32
106	ACE variants and association with brain A $\beta$ levels in Alzheimer's disease. <i>American Journal of Translational Research (discontinued)</i> , <b>2010</b> , 3, 73-80	3	31
105	Vascular genetic factors and human longevity. <i>Mechanisms of Ageing and Development</i> , <b>2004</b> , 125, 169-78	3.6	30
104	Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. <i>Age</i> , <b>2013</b> , 35, 441-53		29

103	Assessment of activation of the plasma kallikrein-kinin system in frontal and temporal cortex in Alzheimer's disease and vascular dementia. <i>Neurobiology of Aging</i> , <b>2012</b> , 33, 1345-55	5.6	29
102	A multi-center study of ACE and the risk of late-onset Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2011</b> , 24, 587-97	4.3	29
101	Accumulation of insoluble amyloid- $\beta$ in down's syndrome is associated with increased BACE-1 and neprilysin activities. <i>Journal of Alzheimer's Disease</i> , <b>2011</b> , 23, 101-8	4.3	28
100	Angiotensins and Alzheimer's disease: a bench to bedside overview. <i>Alzheimer's Research and Therapy</i> , <b>2009</b> , 1, 3	9	28
99	Renin Angiotensin aldosterone system inhibition in controlling dementia-related cognitive decline. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 42 Suppl 4, S575-86	4.3	27
98	Activators and inhibitors of the plasminogen system in Alzheimer's disease. <i>Journal of Cellular and Molecular Medicine</i> , <b>2012</b> , 16, 865-76	5.6	27
97	The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin Targeting (RADAR) Trial. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 61, 803-814	4.3	27
96	Environmental enrichment lessens cognitive decline in APP23 mice without affecting brain sirtuin expression. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 42, 851-64	4.3	27
95	Endothelin-converting enzyme-1 in Alzheimer's disease and vascular dementia. <i>Neuropathology and Applied Neurobiology</i> , <b>2010</b> , 36, 487-97	5.2	27
94	MMP-2, -3 and -9 levels and activity are not related to A $\beta$ load in the frontal cortex in Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , <b>2008</b> , 34, 205-15	5.2	27
93	Repurposing antihypertensive drugs for the prevention of Alzheimer's disease: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , <b>2020</b> , 49, 1132-1140	7.8	27
92	New insights into the genetic etiology of Alzheimer's disease and related dementias.. <i>Nature Genetics</i> , <b>2022</b> ,	36.3	27
91	Angiotensin-III is Increased in Alzheimer's Disease in Association with Amyloid- $\beta$ and Tau Pathology. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 58, 203-214	4.3	26
90	Using Alzgene-like approaches to investigate susceptibility genes for vascular cognitive impairment. <i>Journal of Alzheimer's Disease</i> , <b>2013</b> , 34, 145-54	4.3	26
89	Immunocapture-based fluorometric assay for the measurement of insulin-degrading enzyme activity in brain tissue homogenates. <i>Journal of Neuroscience Methods</i> , <b>2008</b> , 169, 177-81	3	26
88	Polygenic risk score in postmortem diagnosed sporadic early-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2018</b> , 62, 244.e1-244.e8	5.6	25
87	Associations of angiotensin targeting antihypertensive drugs with mortality and hospitalization in primary care patients with dementia. <i>Journal of Alzheimer's Disease</i> , <b>2013</b> , 33, 999-1008	4.3	25
86	New insights on the genetic etiology of Alzheimer's and related dementia		25

85	Regional Increase in the Expression of the BCAT Proteins in Alzheimer's Disease Brain: Implications in Glutamate Toxicity. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 45, 891-905	4.3	24
84	Discovery by the Epistasis Project of an epistatic interaction between the GSTM3 gene and the HHEX/IDE/KIF11 locus in the risk of Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2013</b> , 34, 1309.e1-7	5.6	24
83	Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies. <i>European Journal of Epidemiology</i> , <b>2017</b> , 32, 947-959	12.1	23
82	Prion protein is decreased in Alzheimer's brain and inversely correlates with BACE1 activity, amyloid- $\beta$ levels and Braak stage. <i>PLoS ONE</i> , <b>2013</b> , 8, e59554	3.7	23
81	Calcium channel blockers and Alzheimer's disease: potential relevance in treatment strategies of metabolic syndrome. <i>Journal of Alzheimer's Disease</i> , <b>2012</b> , 30 Suppl 2, S269-82	4.3	23
80	Influence of LRP-1 and apolipoprotein E on amyloid- $\beta$ uptake and toxicity to cerebrovascular smooth muscle cells. <i>Journal of Alzheimer's Disease</i> , <b>2013</b> , 33, 95-110	4.3	23
79	Caveolin-1 and -2 and their relationship to cerebral amyloid angiopathy in Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , <b>2007</b> , 33, 317-27	5.2	23
78	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , <b>2021</b> , 12, 3417	17.4	23
77	Wide-ranging alterations in the brain fatty acid complement of subjects with late Alzheimer's disease as detected by GC-MS. <i>American Journal of Translational Research (discontinued)</i> , <b>2016</b> , 8, 154-65 <sup>3</sup>		22
76	Angiotensin II-inhibiting drugs have no effect on intraneuronal A $\beta$ oligomeric A $\beta$ levels in a triple transgenic mouse model of Alzheimer's disease. <i>American Journal of Translational Research (discontinued)</i> , <b>2011</b> , 3, 197-208	3	21
75	Current knowledge of chromosome 12 susceptibility genes for late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2006</b> , 27, 1537-53	5.6	20
74	DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild cognitive impairment cohorts. <i>Epigenomics</i> , <b>2015</b> , 7, 533-7	4.4	19
73	Association of combination statin and antihypertensive therapy with reduced Alzheimer's disease and related dementia risk. <i>PLoS ONE</i> , <b>2020</b> , 15, e0229541	3.7	19
72	The branched-chain aminotransferase proteins: novel redox chaperones for protein disulfide isomerase--implications in Alzheimer's disease. <i>Antioxidants and Redox Signaling</i> , <b>2014</b> , 20, 2497-513	8.4	19
71	Clusterin mRNA and protein in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2012</b> , 28, 337-44	4.3	19
70	Interaction of insulin and PPAR- $\gamma$ genes in Alzheimer's disease: the Epistasis Project. <i>Journal of Neural Transmission</i> , <b>2012</b> , 119, 473-9	4.3	19
69	Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. <i>Health Technology Assessment</i> , <b>2017</b> , 21, 1-192	4.4	19
68	A Validation Study of Vascular Cognitive Impairment Genetics Meta-Analysis Findings in an Independent Collaborative Cohort. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 53, 981-9	4.3	18



67	Tools for testing decision-making capacity in dementia. <i>Age and Ageing</i> , <b>2018</b> , 47, 778-784	3	18
66	Ethical aspects of research into Alzheimer disease. A European Delphi Study focused on genetic and non-genetic research. <i>Journal of Medical Ethics</i> , <b>2009</b> , 35, 140-4	2.5	17
65	Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 74	9	16
64	TNFR-associated factor-2 (TRAF-2) in Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2009</b> , 30, 1052-60	5.6	16
63	Small RNA modifications in Alzheimer's disease. <i>Neurobiology of Disease</i> , <b>2020</b> , 145, 105058	7.5	16
62	Angiotensin-converting enzyme in cerebrospinal fluid and risk of brain atrophy. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 44, 153-62	4.3	15
61	Mutation analysis of sporadic early-onset Alzheimer's disease using the NeuroX array. <i>Neurobiology of Aging</i> , <b>2017</b> , 49, 215.e1-215.e8	5.6	15
60	Tumour necrosis factor- $\alpha$ (TNF- $\alpha$ ) and miRNA expression in frontal and temporal neocortex in Alzheimer's disease and the effect of TNF- $\alpha$ on miRNA expression in vitro. <i>International Journal of Molecular Epidemiology and Genetics</i> , <b>2011</b> , 2, 156-62	0.9	15
59	Interactions between oestrogen and the renin angiotensin system - potential mechanisms for gender differences in Alzheimer's disease. <i>American Journal of Neurodegenerative Disease</i> , <b>2012</b> , 1, 266-79	7.5	15
58	Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer's (HEART) Trial. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 61, 815-824	4.3	14
57	Investigation of A $\beta$ phosphorylated at serine 8 (pA $\beta$ ) in Alzheimer's disease, dementia with Lewy bodies and vascular dementia. <i>Neuropathology and Applied Neurobiology</i> , <b>2015</b> , 41, 428-44	5.2	14
56	LRP1 expression in cerebral cortex, choroid plexus and meningeal blood vessels: relationship to cerebral amyloid angiopathy and APOE status. <i>Neuroscience Letters</i> , <b>2012</b> , 525, 123-8	3.3	14
55	Antioxidant and anti-inflammatory effects of <i>Scoparia dulcis</i> L. <i>Journal of Medicinal Food</i> , <b>2011</b> , 14, 1576-82	2.8	14
54	Neither sequence variation in the IL-10 gene promoter nor presence of IL-10 protein in the cerebral cortex is associated with Alzheimer's disease. <i>Neuroscience Letters</i> , <b>2006</b> , 408, 141-5	3.3	14
53	Regional differences in effects of APOE $\epsilon$ 4 on cognitive impairment in non-demented subjects. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2011</b> , 32, 135-42	2.6	13
52	Protein and gene expression of tumour necrosis factor receptors I and II and their promoter gene polymorphisms in Alzheimer's disease. <i>Experimental Gerontology</i> , <b>2007</b> , 42, 538-44	4.5	13
51	Angiotensin II-inhibition: effect on Alzheimer's pathology in the aged triple transgenic mouse. <i>American Journal of Translational Research (discontinued)</i> , <b>2012</b> , 4, 151-64	3	13
50	Altered Expression of Human Mitochondrial Branched Chain Aminotransferase in Dementia with Lewy Bodies and Vascular Dementia. <i>Neurochemical Research</i> , <b>2017</b> , 42, 306-319	4.6	12

49	Is amyloid- $\beta$ an innocent bystander and marker in Alzheimer's disease? Is the liability of multivalent cation homeostasis and its influence on amyloid- $\beta$ function the real mechanism?. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 42, 69-85	4.3	11
48	Quantitative measurement of [Na <sup>+</sup> ] and [K <sup>+</sup> ] in postmortem human brain tissue indicates disturbances in subjects with Alzheimer's disease and dementia with Lewy bodies. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 44, 851-7	4.3	11
47	Genetic variation in MME in relation to neprilysin protein and enzyme activity, A $\beta$ levels, and Alzheimer's disease risk. <i>International Journal of Molecular Epidemiology and Genetics</i> , <b>2012</b> , 3, 30-8	0.9	11
46	Is Extracorporeal Shockwave Therapy Combined With Isokinetic Exercise More Effective Than Extracorporeal Shockwave Therapy Alone for Subacromial Impingement Syndrome? A Randomized Clinical Trial. <i>Journal of Orthopaedic and Sports Physical Therapy</i> , <b>2016</b> , 46, 714-25	4.2	11
45	Baseline Results: The Association Between Cardiovascular Risk and Preclinical Alzheimer's Disease Pathology (ASCEND) Study. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 75, 109-117	4.3	10
44	Evidence That Parietal Lobe Fatty Acids May Be More Profoundly Affected in Moderate Alzheimer's Disease (AD) Pathology Than in Severe AD Pathology. <i>Metabolites</i> , <b>2018</b> , 8,	5.6	10
43	Challenges to and Facilitators of Recruitment to an Alzheimer's Disease Clinical Trial: A Qualitative Interview Study. <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 69, 1067-1075	4.3	9
42	Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 72, 525-535	4.3	9
41	Alpha-2-macroglobulin gene, oxidized low-density lipoprotein receptor-1 locus, and sporadic Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2009</b> , 30, 1518-20	5.6	8
40	Evidence that the gene encoding insulin degrading enzyme influences human lifespan. <i>Human Molecular Genetics</i> , <b>2008</b> , 17, 2370-8	5.6	8
39	LRP-1 variation is not associated with risk of Alzheimer's disease. <i>International Journal of Molecular Epidemiology and Genetics</i> , <b>2010</b> , 1, 104-13	0.9	8
38	Can commonly prescribed drugs be repurposed for the prevention or treatment of Alzheimer's and other neurodegenerative diseases? Protocol for an observational cohort study in the UK Clinical Practice Research Datalink. <i>BMJ Open</i> , <b>2016</b> , 6, e012044	3	8
37	BCAT-induced autophagy regulates A $\beta$ load through an interdependence of redox state and PKC phosphorylation-implications in Alzheimer's disease. <i>Free Radical Biology and Medicine</i> , <b>2020</b> , 152, 755-766	7.8	7
36	An exploration of the potential mechanisms and translational potential of five medicinal plants for applications in Alzheimer's disease. <i>American Journal of Neurodegenerative Disease</i> , <b>2013</b> , 2, 70-88	2.5	7
35	Zibotentan, an Endothelin A Receptor Antagonist, Prevents Amyloid- $\beta$ -Induced Hypertension and Maintains Cerebral Perfusion. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 73, 1185-1199	4.3	6
34	What is the impact of regulatory guidance and expiry of drug patents on dementia drug prescriptions in England? A trend analysis in the Clinical Practice Research Datalink. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 51	9	6
33	The association between APOE $\epsilon$ 4 and Alzheimer-type dementia among memory clinic patients is confined to those with a higher education. The DESCRIPA Study. <i>Journal of Alzheimer's Disease</i> , <b>2013</b> , 35, 241-6	4.3	6
32	Differences in allele frequencies of ACE I/D polymorphism between Northern and Southern Europe at different ages. <i>Atherosclerosis</i> , <b>2007</b> , 193, 455-7	3.1	6

31	The Epistasis Project: A Multi-Cohort Study of the Effects of BDNF, DBH, and SORT1 Epistasis on Alzheimer's Disease Risk. <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 68, 1535-1547	4.3	5
30	A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment of subcortical ischaemic vascular dementia (AFFECT): study protocol. <i>Trials</i> , <b>2016</b> , 17, 324	2.8	5
29	Cerebral and systemic hypertension. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2018</b> , 38, 1993-2005	4.5	5
28	Effect of Visit-to-Visit Blood Pressure Variability on Cognitive and Functional Decline in Mild to Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 68, 1499-1510	4.3	4
27	Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , <b>2021</b> , 20, 895-906	24.1	4
26	Divergence in the activity of the N- and C- catalytic domains of ACE1 - implications for the role of the renin-angiotensin system in Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , <b>2019</b> , 7, 57	7.3	3
25	Commentary ( The Renin Angiotensin System in Alzheimers Disease - Do Updates Highlight a Clinical and Biological Dichotomy? ). <i>Current Alzheimer Research</i> , <b>2006</b> , 3, 171-173	3	3
24	Elevated cerebrospinal fluid sodium in hypertensive human subjects with a family history of Alzheimer's disease. <i>Physiological Genomics</i> , <b>2020</b> , 52, 133-142	3.6	3
23	The influence of tumour necrosis factor- $\alpha$ (TNF- $\alpha$ ) on amyloid- $\beta$ (A $\beta$ )-degrading enzymes in vitro. <i>International Journal of Molecular Epidemiology and Genetics</i> , <b>2011</b> , 2, 409-15	0.9	3
22	Blood type gene locus has no influence on ACE association with Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 1767.e1-1767.e2	5.6	2
21	Angiotensin-converting enzyme (ACE) genotypes and disability in hospitalized older patients. <i>Age</i> , <b>2011</b> , 33, 409-19		2
20	Comparison of Antihypertensive Drug Classes for Dementia Prevention. <i>Epidemiology</i> , <b>2020</b> , 31, 852-859	3.1	2
19	Lipid Profiling of Alzheimer's Disease Brain Highlights Enrichment in Glycerol(phospho)lipid, and Sphingolipid Metabolism. <i>Cells</i> , <b>2021</b> , 10,	7.9	2
18	Reply: Atherosclerosis and vascular cognitive impairment neuropathological guideline. <i>Brain</i> , <b>2017</b> , 140, e13	11.2	1
17	Clearance of Abeta from the brain in Alzheimer's disease. Foreword. <i>Brain Pathology</i> , <b>2008</b> , 18, 239	6	1
16	Molecular determinants of human longevity. <i>Advances in Clinical Chemistry</i> , <b>2005</b> , 39, 185-210	5.8	1
15	Presenilin-1 polymorphism and Alzheimer's disease. <i>Lancet</i> , <b>1996</b> , 348, 414	40	1
14	Repurposing antihypertensive drugs for the prevention of Alzheimer's disease: a Mendelian Randomization study		1

- 13 O5-06-05: EXPLORING ACE-2 AS A NOVEL THERAPEUTIC TARGET FOR ALZHEIMER'S DISEASE **2018**, 14, P1659-P1659 1
- 12 UK consensus on pre-clinical vascular cognitive impairment functional outcomes assessment: Questionnaire and workshop proceedings. *Journal of Cerebral Blood Flow and Metabolism*, **2020**, 40, 1402-1414<sup>0</sup> 7.3
- 11 Losartan to slow the progression of mild-to-moderate Alzheimer's disease through angiotensin targeting: the RADAR RCT. *Efficacy and Mechanism Evaluation*, **2021**, 8, 1-72 1.7 0
- 10 Evidence that the Kennedy and polyamine pathways are dysregulated in human brain in cases of dementia with Lewy bodies. *Brain Research*, **2020**, 1743, 146897 3.7 0
- 9 Use of angiotensin-converting enzyme inhibitors for Alzheimer's disease: an update. *Neurodegenerative Disease Management*, **2013**, 3, 511-514 2.8
- 8 Angiotensin receptor blockers associated with decreased incidence and progression of dementia in older men with cardiovascular disease. *Evidence-Based Mental Health*, **2010**, 13, 75 11.1
- 7 Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping.. *Alzheimer's Research and Therapy*, **2022**, 14, 22 9
- 6 Aluminium in the Diet, Cognitive Decline and Dementia **2011**, 2829-2850
- 5 Alcohol Consumption in Predementia and Dementia Syndromes **2011**, 3011-3044
- 4 Association of combination statin and antihypertensive therapy with reduced Alzheimer's disease and related dementia risk **2020**, 15, e0229541
- 3 Association of combination statin and antihypertensive therapy with reduced Alzheimer's disease and related dementia risk **2020**, 15, e0229541
- 2 Association of combination statin and antihypertensive therapy with reduced Alzheimer's disease and related dementia risk **2020**, 15, e0229541
- 1 Association of combination statin and antihypertensive therapy with reduced Alzheimer's disease and related dementia risk **2020**, 15, e0229541